Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 9, 2011, Pages 1675-1682

  Giovacchini, Giampiero ^a   Nicolas, Guillaume ^a   Freidank, Heike ^a   Mindt, Thomas L ^a   Forrer, Flavio ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

90Y DOTATOC; Hyperkalaemia; Neuroendocrine tumours; Targeted radiopeptide therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE; FUROSEMIDE; LYSINE; OCTREOTIDE [3 TYROSINE TETRAACETATE INDIUM 111]; OCTREOTIDE [3 TYROSINE TETRAACETATE YTTRIUM 90]; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; HYPERKALEMIA; KIDNEY TUBULE ABSORPTION; MALE; MENINGIOMA; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; PANCREAS ISLET CELL TUMOR; PARAGANGLIOMA; POTASSIUM BLOOD LEVEL; RADIOACTIVITY; RADIOISOTOPE THERAPY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AMINO ACIDS; FEMALE; HUMANS; HYPERKALEMIA; INFUSION PUMPS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; OCTREOTIDE; POTASSIUM; PROSPECTIVE STUDIES; SOLUTIONS; TIME FACTORS;

EID: 80455164726     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1826-9     Document Type: Article

References (42)

1. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.
2. Waser B, Tamma ML, Cescato R, Maecke HR, Reubi JC. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med. 2009;50:936-41.
3. Esser JP, Krenning EP, Teunissen JJ, Kooij PP, van Gameren AL, Bakker WH, et al. Comparison of [(177) Lu-DOTA (0), Tyr (3)] octreotate and [(177) Lu-DOTA (0), Tyr (3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging. 2006;33:1346-51.
4. Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847-56.
5. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46:62S-6. (Pubitemid 47619020)
6. Forrer F, Waldherr C, Maecke HR, Mueller-Brand J. Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res. 2006;26:703-7. (Pubitemid 43206037)
7. de Jong M, Barone R, Krenning E, Bernard B, Melis M, Visser T, et al. Megalin is essential for renal proximal tubule reabsorption of (111) In-DTPA-octreotide. J Nucl Med. 2005;46:1696-700. (Pubitemid 46211593)
8. Mogensen CE, Sølling. Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest. 1977;37:477-86. (Pubitemid 8390150)
9. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25:201-12. (Pubitemid 28130048)
10. Barone R, Pauwels S, De Camps J, Krenning EP, Kvols LK, Smith MC, et al. Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. Nephrol Dial Transplant. 2004;19:2275-81. (Pubitemid 39214121)
11. Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: A phase I study. Eur J Nucl Med Mol Imaging. 2003;30:207-16. (Pubitemid 36686839)
12. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30:9-15. (Pubitemid 36692887)
13. Rolleman EJ, Melis M, Valkema R, Boerman OC, Krenning EP, de Jong M. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging. 2010;37:1018-31.
14. Bernard BF, Krenning EP, Breeman WA, Rolleman EJ, Bakker WH, Visser TJ, et al. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med. 1997;38:1929-33. (Pubitemid 28030925)
15. Bushinsky DA, Gennari FJ. Life-threatening hyperkalemia induced by arginine. Ann Intern Med. 1978;89:632-4. (Pubitemid 9020980)
16. Dursun I, Sahin M. Difficulties in maintaining potassium homeostasis in patients with heart failure. Clin Cardiol. 2006;29:388-92. (Pubitemid 44353325)
17. Weiner ID, Wingo CS. Hyperkalemia: A potential silent killer. J Am Soc Nephrol. 1998;9:1535-43. (Pubitemid 28354566)
18. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90) Y-DOTATOC. J Nucl Med. 2002;43:610-6. (Pubitemid 34507110)
19. Forrer F, Uusijarvi H, Waldherr C, Cremonesi M, Bernhardt P, Mueller-Brand J, et al. A comparison of (111) In-DOTATOC and (111) In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1257-62. (Pubitemid 39222489)
20. Brater DC, Fox WR, Chennavasin P. Electrolyte excretion patterns. Intravenous and oral doses of bumetanide compared to furosemide. J Clin Pharmacol. 1981;21:599-603. (Pubitemid 12166945)
21. Valentin J (ed). P103: The 2007 Recommendations of the International Commission on Radiological Protection. Ann ICRP 2008;37(2-4):1-332.
22. Ponce SP, Jennings AE, Madias NE, Harrington JT. Drug-induced hyperkalemia. Medicine (Baltimore). 1985;64:357-70. (Pubitemid 16197701)
23. Sica DA, Gehr TW, Yancy C. Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism. Congest Heart Fail. 2003;9:224-9.
24. Levinsky NG, Tyson I, Miller RB, Relman AS. The relation between amino acids and potassium in isolated rat muscle. J Clin Invest. 1962;41:480-7.
25. Dickerman HW, Walker WG. Effect of cationic amino acid infusion on potassium metabolism in vivo. Am J Physiol. 1964;206:403-8.
26. Merimee TJ, Lillicrap DA, Rabinowitz D. Effect of arginine on serum-levels of human growth-hormone. Lancet. 1965;2:668-70.
27. Nyirenda MJ, Tang JI, Padfield PL, Seckl JR. Hyperkalaemia. BMJ. 2009;339:b4114.
28. Obialo CI, Ofili EO, Mirza T. Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease. Am J Cardiol. 2002;90:663-5. (Pubitemid 35264552)
29. Vereijken TL, Bellersen L, Groenewoud JM, Knubben L, Baltussen L, Kramers C. Risk calculation for hyperkalaemia in heart failure patients. Neth J Med. 2007;65:208-11. (Pubitemid 47007914)
30. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med. 1998;158:26-32. (Pubitemid 28070442)
31. Herman E, Rado J. Fatal hyperkalemic paralysis associated with spironalactone. Observation on a patient with severe renal disease and refractory edema. Arch Neurol. 1966;15:74-7.
32. Desai AS. Hyperkalemia in patients with heart failure: incidence, prevalence, and management. Curr Heart Fail Rep. 2009;6:272-80.
33. Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, et al. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging. 2003;30:510-8. (Pubitemid 36559829)
34. Cox M, Sterns RH, Singer I. The defense against hyperkalemia: the roles of insulin and aldosterone. N Engl J Med. 1978;299:525-32. (Pubitemid 9053820)
35. Kim HJ, Han SW. Therapeutic approach to hyperkalemia. Nephron. 2002;92 Suppl 1:33-40.
36. Vegt E, Wetzels JF, Russel FG, Masereeuw R, Boerman OC, van Eerd JE, et al. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med. 2006;47:432-6. (Pubitemid 46768485)
37. van Eerd JE, Vegt E, Wetzels JF, Russel FG, Masereeuw R, Corstens FH, et al. Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. J Nucl Med. 2006;47:528-33. (Pubitemid 46768496)
38. Vegt E, van Eerd JE, Eek A, Oyen WJ, Wetzels JF, de Jong M, et al. Reducing renal uptake of radiolabeled peptides using albumin fragments. J Nucl Med. 2008;49:1506-11.
39. Gielkens HA, Lamers CB, Masclee AA. Effect of amino acids on lower esophageal sphincter characteristics and gastroesophageal reflux in humans. Dig Dis Sci. 1998;43:840-6. (Pubitemid 28176475)
40. Hertz P, Richardson JA. Arginine-induced hyperkalemia in renal failure patients. Arch Intern Med. 1972;130:778-80.
41. Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1038-46. (Pubitemid 38915663)
42. de Jong M, Rolleman EJ, Bernard BF, Visser TJ, Bakker WH, Breeman WA, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med. 1996;37:1388-92. (Pubitemid 26330680)